News
Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...
Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...
2hon MSN
Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug. They found that the drug slowed cognitive decline by 46% in a group of patients ...
The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results